I'm a professional

Healthcare professional

Clinical evidence, integration details, and product specifications for oncology teams.

Enter

I'm a patient or caregiver

Patient or caregiver

Information about Cureety as a daily companion during your treatment journey.

Enter
  1. Resources
  2. Our Studies
  3. CANIQOL

Interventional • Organizational benefit

CANIQOL

Organizational benefit

80

Patients enrolled in the program

15

Participating center(s) across the study

Study description

An interventional, one-arm study to assess remote monitoring of patients using the Cabozantinib/Nivolumab combination in advanced, metastatic kidney cancer.

Key results

Recruitment started in October 2025 Study ongoing

Publication

https://www.asco.org/abstracts-presentations/256910

Research collaboration

Discuss this study with our research team

Questions about methodology, results, or potential collaborations — our team is available to engage with researchers, clinicians and life sciences partners.

Empowering better oncology care

© 2026 Cureety — All rights reserved.

Privacy NoticeTerms of Use

Cureety Inc.

Empowering better oncology care

© 2026 Cureety — All rights reserved.

Privacy NoticeTerms of Use

Cureety Inc.